PaulKwoMD

Gastroenterology • Redwood City, CA

Hepatology & Liver Transplantation

Professor of Medicine, Stanford University

Join to view full profile

Dr. Kwo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kwo's full profile

Already have an account?

Office
430 Broadway, Pavilion C
3rd Floor
Redwood City, CA 94063
Phone+1 650-723-7040
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1992 - 1995
University of MarylandResidency, Internal Medicine, 1988 - 1991
Wayne State University School of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 2016 - 2025
IN State Medical License 1995 - 2017
MN State Medical License 1992 - 1995
MD State Medical License 1990 - 1992
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
Indianapolis Monthly Castle Connolly, 2007, 2009-2011, 2013
Fellow (FACG) American College of Gastroenterology

Clinical Trials

Study of Telaprevir in Subjects With Hepatic Impairment Start of enrollment: 2007 Sep 01
Completed
Phase 1
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation Start of enrollment: 2013 Jun 01
Completed
Early Phase 1
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
Completed
Phase 2
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV Start of enrollment: 2021 Dec 21
Active, not recruiting
Phase 3
Roles: Contact, Principal Investigator
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Start of enrollment: 2018 Dec 01
Completed
Phase 3
Roles: Principal Investigator, Contact
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Start of enrollment: 2023 Mar 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Treatment of Autoimmune Hepatitis.
Aparna Goel, Paul Kwo> ;Clinics in Liver Disease. 2024 Feb 1
1 citations
Use and Outcomes of Hepatitis B Virus-positive Grafts for Kidney or Heart Transplantation in the United States From 1999 to 2021.
Ashwani K Singal, K Rajender Reddy, Mindie H Nguyen, Zobair Younossi, Paul Kwo, Yong-Fang Kuo> ;Transplantation. 2024 Mar 1
Alcohol Use in Liver Transplant Recipients With Alcohol-related Liver Disease: A Comparative Assessment of Relapse Prediction Models.
Mai Sedki, Allison Kwong, Meera Bhargava, Aijaz Ahmed, Tami Daugherty, Paul Kwo, Deepti Dronamraju, Radhika Kumari, W Ray Kim, Carlos Esquivel, Marc Melcher, C Andrew ...> ;Transplantation. 2024 Mar 1
Hepatitis C Screening in Post-Baby Boomer Generation Americans: One Size Does Not Fit All.
Pimsiri Sripongpun, Prowpanga Udompap, Ajitha Mannalithara, N Lance Downing, Anna A Vidovszky, Allison J Kwong, Aparna Goel, Paul Y Kwo, W Ray Kim> ;Mayo Clinic Proceedings. 2023 Sep 1
Viral Hepatitis and Acute-on-Chronic Liver Failure.
Talal Khushid Bhatti, Ashwani K Singal, Paul Y Kwo> ;Clinics in Liver Disease. 2023 Aug 1
Immunoglobulin G4-Seronegative Autoimmune Cholangiopathy With Pancreatic and Hepatic Involvement Mimicking as Primary Sclerosing Cholangitis.
Sudharshan Achalu, Mike T Wei, Subhas Banerjee, Pejman Ghanouni, Neeraja Kambham, Paul Y Kwo, Berry, R.> ;ACG Case Reports Journal. 2023 Apr 1
4 citations
Impact of COVID-19 on Liver Transplant Activity in the USA: Variation by Etiology and Cirrhosis Complications.
Yong-Fang Kuo, Paul Kwo, Robert J Wong, Ashwani K Singal> ;Journal of Clinical and Translational Hepatology. 2023 Feb 28
Portopulmonary Hypertension.
Yu Kuang Lai, Paul Y Kwo> ;Clinics in Liver Disease. 2023 Feb 1
7 citations
Practical Management of HRS-AKI in the Era of Terlipressin: What the Gastroenterologist Needs to Know.
Florence Wong, Paul Kwo> ;The American Journal of Gastroenterology. 2023 Jun 1
7 citations
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US.
Ashwani K Singal, Yong-Fang Kuo, K Rajender Reddy, Ramon Bataller, Paul Kwo> ;Alimentary Pharmacology & Therapeutics. 2022 Nov 1
2 citations
Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B.
Leslie Y Kam, Daniel Q Huang, Alfred F Tobias, Kitty Poon, Linda Henry, Paul Kwo, Ramsey Cheung, Mindie H Nguyen> ;Alimentary Pharmacology & Therapeutics. 2022 Dec 1
17 citations
Epidemiology and Disease Burden of Alcohol Associated Liver Disease.
Aysha Aslam, Paul Y Kwo> ;Journal of Clinical and Experimental Hepatology. 2022 Sep 20
2 citations
Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites.
Omar Alshuwaykh, Amanda Cheung, Aparna Goel, Allison Kwong, Renumathy Dhanasekaran, T Tara Ghaziani, Aijaz Ahmed, Tami Daugherty, Deepti Dronamraju, Radhika Kumari, Mi...> ;BMC Gastroenterology. 2022 Sep 5
4 citations
Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
W Ray Kim, Ajitha Mannalithara, Paul Y Kwo, C Andrew Bonham, Allison Kwong> ;Hepatology. 2023 Mar 1
12 citations
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.
Man-Fung Yuen, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B Han...> ;Journal of Hepatology. 2022 Sep 1
3 citations
Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
Omar Alshuwaykh, Tami Daugherty, Amanda Cheung, Aparna Goel, Renumathy Dhanasekaran, T Tara Ghaziani, Aijaz Ahmed, Deepti Dronamraju, Radhika Kumari, Allison Kwong, Mi...> ;Hepatology Communications. 2022 Nov 1
3 citations
Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021.
Saad Emhmed Ali, Philip Vutien, C Andrew Bonham, Charles Landis, Paul Kwo, Carlos Esquivel, Mindie H Nguyen> ;Liver Transplantation. 2023 Jan 1
17 citations
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.
Mark S Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff, Hie-Won L Hann, Douglas T Dieterich, Ronald G Nahass, James S Park, Sing Chan, Steven-Huy B ...> ;Journal of Hepatology. 2022 Nov 1
Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
Calvin Q Pan, Ira M Jacobson, Paul Martin, Paul Kwo, Joseph Lim, Steven-Huy B Han, Ke-Qin Hu, Joseph Ahn, Myron J Tong> ;Hepatology. 2022 Jun 1
3 citations
Impact of medical eligibility criteria and OPTN policy on simultaneous liver kidney allocation and utilization.
Ashwani K Singal, Yong-Fang Kuo, Paul Kwo, Nadim Mahmud, Pratima Sharma, Mitra K Nadim> ;Clinical Transplantation. 2022 Jul 1
2 citations
Blood phosphatidylethanol testing and liver transplant eligibility selection: A step closer.
Ashwani K Singal, Paul Kwo> ;Alcoholism, Clinical and Experimental Research. 2022 May 1
5 citations
First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Calvin Q Pan, Nezam H Afdhal, Victor Ankoma-Sey, Ho Bae, Michael P Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie-Won Hann, W Ray Kim, Paul Kwo, Scott Milli...> ;Hepatology Communications. 2022 Aug 1
2 citations
Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study.
Douglas Halket, Jimmy Dang, Anuradha Phadke, Channa Jayasekera, W Ray Kim, Paul Kwo, Lance Downing, Aparna Goel> ;Journal of General Internal Medicine. 2022 Oct 1
16 citations
Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
Ashwani K. Singal, Paul Y. Kwo, Allison J. Kwong, Suthat Liangpunsakul, Alexandre Louvet, Pranoti Mandrekar, Craig J. McClain, Jessica L. Mellinger, Gyongyi Szabo, Nor...> ;Hepatology. 2021 Sep 8
15 citations
Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome.
Allison J. Kwong, W. Ray Kim, Paul Y. Kwo, Uerica Wang, Xingxing S. Cheng> ;Liver Transplantation. 2021 Aug 1
Join now to see all

Journal Articles

Diagnosis and Management of Primary Biliary Cholangitis
Zobair M Younossi, Kris V Kowdley, Ira M Jacobson, Mitchell L Shiffman, Paul Kwo, Nature
Response to Perrella Et Al
Paul Y Kwo, Mitchell L Shiffman, Nature

Lectures

Liver Transplantation: Selection and Controversies
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/7/2018
Viral Hepatitis: Where We Are in 2018
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/6/2018

Authored Content

Reflections on Key Presentations at ACG 2021November 2021

Press Mentions

DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a TrialMay 7th, 2019
DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial ResultsMay 3rd, 2019
Phase 2 Data Show Treatment Efficacy in 'Difficult-to-Cure' Hepatitis C PatientsApril 16th, 2016
Join now to see all